MissionIR Articles
-
Soligenix (NASDAQ: SNGX) Positioning for Impact in Growing Rare-Disease Landscape
As the global burden of rare diseases continues to rise, there is increasing urgency for innovative therapies that address unmet medical needs. More than 300 million people worldwide live with one or more rare diseases,…
-
MissionIRNewsBreaks – RiVax(R) Positions Soligenix Inc. (NASDAQ: SNGX) in Growing Biodefense Preparedness Efforts
Soligenix (NASDAQ: SNGX), a biopharmaceutical company focused on biodefense solutions, was featured in a recent article discussing its development of a vaccine candidate known as RiVax(R) to protect against ricin exposure. These efforts position the…
-
Soligenix Inc. (NASDAQ: SNGX) Announces Positive Phase 2 Data for Rare Inflammatory Disease
Behçet’s disease is a rare, chronic inflammatory condition that can cause recurrent, painful ulcers, eye inflammation and systemic complications that significantly affect quality of life. Because available treatments are limited and often inconsistent, clinical trial…
-
MissionIRNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Reaches Enrollment Milestone in Phase 3 FLASH2 Trial for HyBryte(TM)
Soligenix (NASDAQ: SNGX) is a New Jersey-based biopharmaceutical company focused on developing products to treat rare diseases where there is an unmet medical need. The company recently received updated analysis from Zacks Small-Cap Research following its…
-
Soligenix Inc. (NASDAQ: SNGX) Extends SGX302 Clinical Success in Phase 2A Psoriasis Study
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products for rare diseases where unmet medical need exists, announced extended top line results from its Phase 2a clinical trial of SGX302 (synthetic…
-
Soligenix Inc. (NASDAQ: SNGX) Advances Ricin Vaccine amid Toxin Threat
A recent “Times of India” report spotlighted the danger posed by ricin, a highly toxic plant-derived compound with no known antidote and a history of attempted misuse by extremist actors. Soligenix (NASDAQ: SNGX), a biopharmaceutical company focused…
-
MissionIRNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Publishes Positive Phase 2a SGX945 Data in Behçet’s Disease
Soligenix (NASDAQ: SNGX) announced that results from its Phase 2a proof-of-concept study evaluating SGX945 (dusquetide) for the treatment of aphthous ulcers associated with Behçet’s Disease have been published in Rheumatology (Oxford), reporting beneficial effects in seven of eight patients…
-
MissionIRNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Reports Extended Phase 2a Results for SGX302 Gel in Mild-to-Moderate Psoriasis
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on treatments for rare diseases with unmet medical need, reported extended results from its ongoing Phase 2a trial evaluating SGX302 (synthetic hypericin) for mild-to-moderate psoriasis, including outcomes…
-
MissionIRNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Featured in NetworkNewsAudio APR on Urgent Need for Rare Disease Therapies
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company developing treatments for rare diseases, is highlighted in a new NetworkNewsAudio APR titled “Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now.” The…
-
Soligenix Inc. (NASDAQ: SNGX) Receives Strong Vote of Confidence from Zacks Report Despite Muted Market Response to Clinical Milestone
When a late-stage clinical trial reports response rates nearly double what researchers expected, yet the stock market barely reacts, seasoned analysts take notice and wonder if investors are missing something significant. Soligenix (NASDAQ: SNGX), a…
-
MissionIRNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Featured in BioMedWire Editorial on Rare Disease Therapies
Soligenix (NASDAQ: SNGX), announces its inclusion in a BioMedWire editorial examining the urgent rise of chronic and rare diseases in aging populations. With more than 30 million Americans living with rare disorders that often lack…
-
MissionIRNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Featured in BioMedWire Editorial Highlighting HyBryte(TM) and Rare Disease Policy
Soligenix (NASDAQ: SNGX) was featured in a BioMedWire editorial titled “Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now,” which examines the growing burden of rare diseases affecting more than…
-
Soligenix Inc. (NASDAQ: SNGX) Reaches Key Enrollment Milestone in Phase 3 Trial with Encouraging Blinded Response Rate
In a pivotal advancement for patients suffering from a rare form of skin cancer, Soligenix (NASDAQ: SNGX) has achieved a critical clinical trial milestone that brings its investigational treatment significantly closer to potential FDA approval. The company…
-
MissionIRNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Advancing Heat-Stable Vaccine Platform with New Peer-Reviewed Data
Soligenix (NASDAQ: SNGX) is a late-stage biopharmaceutical company specializing in biodefense and rare disease vaccines. The company recently published a peer-reviewed summary of new scientific data demonstrating long-term high-temperature stability of its protein subunit vaccine platform designed for…
-
Soligenix Inc. (NASDAQ: SNGX) Elevates Advisory Network as Rare Disease Strategy Advances
Soligenix (NASDAQ: SNGX) is entering a new phase of strategic breadth and influence with the appointment of a seasoned, high-level scientific and policy adviser who brings rarefied experience at the intersection of economics, government and…
-
Soligenix Inc. (NASDAQ: SNGX) Strengthens CTCL Program as DMC Flags No Safety Issues
In a key development that underscores the advancing clinical trajectory of its lead therapy, Soligenix (NASDAQ: SNGX) announced that the Data Monitoring Committee (“DMC”) overseeing its confirmatory Phase 3 FLASH2 trial of HyBryte(TM) has reported…
-
MissionIRNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Completes Enrollment for Interim Analysis in Phase 3 FLASH2 Study of HyBryte
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company developing treatments for rare diseases with unmet medical need, completed enrollment of the 50 patients required for the interim analysis in its 80-patient confirmatory Phase 3 FLASH2 study…
-
MissionIRNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Highlights Key Clinical Progress and Reports Q3 2025 Financial Results
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company advancing treatments for rare diseases with unmet medical need, reported third quarter 2025 results and outlined upcoming milestones, including top-line Phase 2a results for SGX302 in psoriasis and…
-
Soligenix Inc. (NASDAQ: SNGX) Strengthens Financial Foundation to Advance Multiple Value Drivers
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on rare diseases and biodefense programs, continues to fortify its financial position as it advances toward a series of pivotal and potentially transformational milestones. Following a series…
-
Soligenix Inc. (NASDAQ: SNGX) Strengthens Advisory Leadership in Cutaneous T-Cell Lymphoma
Soligenix (NASDAQ: SNGX), a clinical-stage biotechnology company focused on rare diseases and public health solutions, has rejuvenated its U.S. Medical Advisory Board for cutaneous T-cell lymphoma (“CTCL”), placing fresh expertise and leadership at the center…
Search Articles
Latest Articles
- MissionIRNewsBreaks – Safe Pro Group Inc. (NASDAQ: SPAI) Demonstrates AI Drone Threat Detection in U.S. Army Live Fire Exercise
- MissionIRNewsBreaks – Polyrizon Ltd. (NASDAQ: PLRZ) Closes $3.5 Million Registered Direct Offering and Concurrent Private Placement
- MissionIRNewsBreaks – Massimo Group (NASDAQ: MAMO) Enters Strategic Cooperation With AIBO Robotics to Advance AI-Driven Automation and Smart Mobility
- Compact Proton Therapy Delivery Helps Make the Treatment More Accessible for Cancer Patients
- MissionIRNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Forms NRx Defense Systems Subsidiary to Advance Neuroplastic Therapies for Military and Government Applications